Cargando…
An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer
Although colorectal cancer is increasingly being diagnosed in older patients, their number is largely underrepresented in phase II or III clinical trials. Consequently, guidelines and the SIOG recommendations are not sufficiently clear regarding the treatment of these patients, particularly when che...
Autores principales: | Rosati, Gerardo, Montrone, Michele, Pacilio, Carmen, Colombo, Alfredo, Cicero, Giuseppe, Paragliola, Fernando, Vaia, Angelo, Annunziata, Luigi, Bilancia, Domenico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739901/ https://www.ncbi.nlm.nih.gov/pubmed/36498683 http://dx.doi.org/10.3390/jcm11237108 |
Ejemplares similares
-
Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report
por: Rosati, Gerardo, et al.
Publicado: (2018) -
Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy
por: Rosati, Gerardo, et al.
Publicado: (2022) -
Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer Aged at Least 75 Years: A Post-Hoc Subgroup Analysis of Three Phase II Trials
por: Rosati, Gerardo, et al.
Publicado: (2019) -
Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial
por: Avallone, Antonio, et al.
Publicado: (2021) -
Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
por: Iacovino, Marialucia, et al.
Publicado: (2020)